Quarterly report · Q2
3055.TEDINET S100S5VW
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥135.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥262.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥129.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥147.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥137.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥140.6bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥88.9bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥80.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.7bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥57.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥56.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥22.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥22.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥122m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥596m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥633m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥33.35 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.66 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.94 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥29m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥615m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥27m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥794m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥263m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥530m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥33m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥31.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥283m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥581m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥106m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥100.0bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥95.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥502m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥142.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥135.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥910m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥631m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥20m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥251m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥777m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥172m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥92.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥88.0bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥627m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥136.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥129.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 545
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investment securities inv cf | Prior1YTDDuration | -68000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -70000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 566000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 8000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 8000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -1000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -1000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -122000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -1810000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -0 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -383000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -278000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -214000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -273000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -34000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -43000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -633000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -596000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 313000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 4088000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 21091000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 18022000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 21404000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 22110000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 87990000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 32713000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6710000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1988000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 217000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 30000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 129650000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 4549000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 251000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 631000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 1572000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 7012000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 92540000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 32964000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6716000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1990000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 848000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 1602000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 136663000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 627000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |